Relay Therapeutics Analyst Ratings
Relay Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 145.16% | HC Wainwright & Co. | $33 → $19 | Maintains | Buy |
| 10/17/2023 | 325.81% | HC Wainwright & Co. | $30 → $33 | Maintains | Buy |
| 08/17/2023 | 287.1% | HC Wainwright & Co. | $32 → $30 | Maintains | Buy |
| 08/09/2023 | 325.81% | Oppenheimer | → $33 | Reiterates | Outperform → Outperform |
| 06/09/2023 | 312.9% | HC Wainwright & Co. | $46 → $32 | Maintains | Buy |
| 05/05/2023 | 209.68% | JMP Securities | $28 → $24 | Maintains | Market Outperform |
| 04/20/2023 | 61.29% | Jefferies | $16 → $12.5 | Upgrades | Underperform → Hold |
| 04/20/2023 | 338.71% | Stifel | $38 → $34 | Maintains | Buy |
| 04/19/2023 | 274.19% | JP Morgan | $42 → $29 | Maintains | Overweight |
| 04/19/2023 | 261.29% | JMP Securities | → $28 | Reiterates | → Market Outperform |
| 04/19/2023 | 274.19% | Raymond James | → $29 | Upgrades | Outperform → Strong Buy |
| 04/19/2023 | 93.55% | Barclays | $23 → $15 | Maintains | Equal-Weight |
| 04/18/2023 | 325.81% | Oppenheimer | → $33 | Maintains | Outperform |
| 04/13/2023 | 274.19% | Raymond James | → $29 | Initiates Coverage On | → Outperform |
| 04/05/2023 | 441.94% | JP Morgan | $45 → $42 | Maintains | Overweight |
| 03/07/2023 | 493.55% | HC Wainwright & Co. | $43 → $46 | Maintains | Buy |
| 02/03/2023 | 325.81% | Oppenheimer | → $33 | Initiates Coverage On | → Outperform |
| 01/19/2023 | 261.29% | JMP Securities | $38 → $28 | Maintains | Market Outperform |
| 11/07/2022 | 454.84% | HC Wainwright & Co. | $50 → $43 | Maintains | Buy |
| 09/30/2022 | 196.77% | Barclays | → $23 | Initiates Coverage On | → Equal-Weight |
| 09/14/2022 | 390.32% | JMP Securities | $35 → $38 | Maintains | Market Outperform |
| 09/12/2022 | 545.16% | HC Wainwright & Co. | $46 → $50 | Maintains | Buy |
| 09/02/2022 | 416.13% | Stifel | → $40 | Initiates Coverage On | → Buy |
| 08/09/2022 | 493.55% | HC Wainwright & Co. | $47 → $46 | Maintains | Buy |
| 06/06/2022 | 67.74% | Jefferies | → $13 | Initiates Coverage On | → Underperform |
| 05/24/2022 | 441.94% | Goldman Sachs | $49 → $42 | Maintains | Buy |
| 05/10/2022 | 506.45% | HC Wainwright & Co. | $54 → $47 | Maintains | Buy |
| 05/09/2022 | 351.61% | JMP Securities | $50 → $35 | Maintains | Market Outperform |
| 02/01/2022 | 480.65% | Berenberg | → $45 | Initiates Coverage On | → Buy |
| 08/17/2021 | 596.77% | HC Wainwright & Co. | $57 → $54 | Maintains | Buy |
| 07/21/2021 | 545.16% | B of A Securities | → $50 | Initiates Coverage On | → Buy |
| 01/29/2021 | 570.97% | JP Morgan | $36 → $52 | Maintains | Neutral |
| 12/15/2020 | 635.48% | HC Wainwright & Co. | $54 → $57 | Maintains | Buy |
| 12/08/2020 | 751.61% | JMP Securities | → $66 | Initiates Coverage On | → Market Outperform |
| 11/05/2020 | 596.77% | HC Wainwright & Co. | → $54 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/08/2023 | 145.16% | HC Wainwright & Co. | 33 美元 → 19 美元 | 維護 | 買 |
| 10/17/2023 | 325.81% | HC Wainwright & Co. | 30 美元 → 33 美元 | 維護 | 買 |
| 08/17/2023 | 287.1% | HC Wainwright & Co. | 32 美元 → 30 美元 | 維護 | 買 |
| 08/09/2023 | 325.81% | 奧本海默 | → 33 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 06/09/2023 | 312.9% | HC Wainwright & Co. | 46 美元 → 32 美元 | 維護 | 買 |
| 05/05/2023 | 209.68% | JMP 證券 | 28 美元 → 24 美元 | 維護 | 市場表現跑贏大盤 |
| 04/20/2023 | 61.29% | 傑富瑞集團 | 16 美元 → 12.5 美元 | 升級 | 表現不佳 → 持有 |
| 04/20/2023 | 338.71% | Stifel | 38 美元 → 34 美元 | 維護 | 買 |
| 04/19/2023 | 274.19% | 摩根大通 | 42 美元 → 29 美元 | 維護 | 超重 |
| 04/19/2023 | 261.29% | JMP 證券 | → 28 美元 | 重申 | → 市場跑贏大盤 |
| 04/19/2023 | 274.19% | 雷蒙德·詹姆 | → 29 美元 | 升級 | 跑贏大盤 → 強勢買入 |
| 04/19/2023 | 93.55% | 巴克萊 | 23 美元 → 15 美元 | 維護 | 重量相等 |
| 04/18/2023 | 325.81% | 奧本海默 | → 33 美元 | 維護 | 跑贏大盤 |
| 04/13/2023 | 274.19% | 雷蒙德·詹姆 | → 29 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 04/05/2023 | 441.94% | 摩根大通 | 45 美元 → 42 美元 | 維護 | 超重 |
| 03/07/2023 | 493.55% | HC Wainwright & Co. | 43 美元 → 46 美元 | 維護 | 買 |
| 02/03/2023 | 325.81% | 奧本海默 | → 33 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 01/19/2023 | 261.29% | JMP 證券 | 38 美元 → 28 美元 | 維護 | 市場表現跑贏大盤 |
| 2022 年 7 月 11 日 | 454.84% | HC Wainwright & Co. | 50 美元 → 43 美元 | 維護 | 買 |
| 09/30/2022 | 196.77% | 巴克萊 | → 23 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
| 09/14/2022 | 390.32% | JMP 證券 | 35 美元 → 38 美元 | 維護 | 市場表現跑贏大盤 |
| 09/12/2022 | 545.16% | HC Wainwright & Co. | 46 美元 → 50 美元 | 維護 | 買 |
| 09/02/2022 | 416.13% | Stifel | → 40 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/09/2022 | 493.55% | HC Wainwright & Co. | 47 美元 → 46 美元 | 維護 | 買 |
| 2022 年 6 月 6 日 | 67.74% | 傑富瑞集團 | → 13 美元 | 啓動覆蓋範圍開啓 | → 表現不佳 |
| 2022 年 5 月 24 日 | 441.94% | 高盛 | 49 美元 → 42 美元 | 維護 | 買 |
| 05/10/2022 | 506.45% | HC Wainwright & Co. | 54 美元 → 47 美元 | 維護 | 買 |
| 05/09/2022 | 351.61% | JMP 證券 | 50 美元 → 35 美元 | 維護 | 市場表現跑贏大盤 |
| 2022 年 1 月 2 日 | 480.65% | 貝倫貝格 | → 45 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 8 月 17 日 | 596.77% | HC Wainwright & Co. | 57 美元 → 54 美元 | 維護 | 買 |
| 07/21/2021 | 545.16% | B of A 類證券 | → 50 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 1 月 29 日 | 570.97% | 摩根大通 | 36 美元 → 52 美元 | 維護 | 中立 |
| 2020 年 12 月 15 日 | 635.48% | HC Wainwright & Co. | 54 美元 → 57 美元 | 維護 | 買 |
| 12/08/2020 | 751.61% | JMP 證券 | → 66 美元 | 啓動覆蓋範圍開啓 | → 市場跑贏大盤 |
| 2020 年 5 月 11 日 | 596.77% | HC Wainwright & Co. | → 54 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Relay Therapeutics (RLAY)?
Relay Therapeutics（RLAY）的目標價格是多少？
The latest price target for Relay Therapeutics (NASDAQ: RLAY) was reported by HC Wainwright & Co. on November 8, 2023. The analyst firm set a price target for $19.00 expecting RLAY to rise to within 12 months (a possible 145.16% upside). 18 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月8日公佈了Relay Therapeutics（納斯達克股票代碼：RLAY）的最新目標股價。該分析公司將目標股價定爲19.00美元，預計RLAY將在12個月內升至12個月內（可能上漲145.16％）。去年有18家分析公司公佈了評級。
What is the most recent analyst rating for Relay Therapeutics (RLAY)?
Relay Therapeutics（RLAY）的最新分析師評級是多少？
The latest analyst rating for Relay Therapeutics (NASDAQ: RLAY) was provided by HC Wainwright & Co., and Relay Therapeutics maintained their buy rating.
Relay Therapeutics（納斯達克股票代碼：RLAY）的最新分析師評級由HC Wainwright & Co. 提供，Relay Therapeutics維持買入評級。
When is the next analyst rating going to be posted or updated for Relay Therapeutics (RLAY)?
Relay Therapeutics（RLAY）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relay Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relay Therapeutics was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Relay Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Relay Therapeutics的最新評級是在2023年11月8日公佈的，因此您應該預計下一個評級將在2024年11月8日左右公佈。
Is the Analyst Rating Relay Therapeutics (RLAY) correct?
分析師評級 Relay Therapeutics (RLAY) 是否正確？
While ratings are subjective and will change, the latest Relay Therapeutics (RLAY) rating was a maintained with a price target of $33.00 to $19.00. The current price Relay Therapeutics (RLAY) is trading at is $7.75, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Relay Therapeutics（RLAY）評級維持不變，目標股價爲33.00美元至19.00美元。Relay Therapeutics（RLAY）目前的交易價格爲7.75美元，超出了分析師的預期區間。